<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03208790</url>
  </required_header>
  <id_info>
    <org_study_id>TQ-OPML</org_study_id>
    <nct_id>NCT03208790</nct_id>
  </id_info>
  <brief_title>Clinical and Immunohisochemical Evaluation of Chemopreventive Effect of Thymoquinone on Oral Potentially Malignant Lesions.</brief_title>
  <official_title>Clinical And Immunohistochemical Evaluation Of The Cancer Chemopreventive Effect Of Thymoquinone Compared To A Placebo On Oral Potentially Malignant Lesions Among An Egyptian Population : A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present randomized, controlled, parallel-grouped trial includes 81 patients (aged 18 to
      75 years) suffering from oral potential premalignant lesions. Patients will be randomly
      assigned into 3 equal groups: Group A:Thymoquinone group 100mg Group B:Thymoquinone group
      200mg Group C:Control group (placebo)
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Medication satisfaction</measure>
    <time_frame>3 months</time_frame>
    <description>Treatment Satisfaction Questionnaire for Medication (TSQM-II)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical response</measure>
    <time_frame>baseline</time_frame>
    <description>dimension of the lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical response</measure>
    <time_frame>3 months</time_frame>
    <description>dimension of the lesion</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Molecular evidence of malignant transformation</measure>
    <time_frame>baseline</time_frame>
    <description>Immunohistochemical analysis using specific markers for cell proliferation(ki67)</description>
  </other_outcome>
  <other_outcome>
    <measure>Molecular evidence of malignant transformation</measure>
    <time_frame>3 months</time_frame>
    <description>Immunohistochemical analysis using specific markers for cell proliferation(ki67)</description>
  </other_outcome>
  <other_outcome>
    <measure>Molecular evidence of malignant transformation</measure>
    <time_frame>baseline</time_frame>
    <description>Immunohistochemical analysis using specific markers for apoptosis(caspase3)</description>
  </other_outcome>
  <other_outcome>
    <measure>Molecular evidence of malignant transformation</measure>
    <time_frame>3 months</time_frame>
    <description>Immunohistochemical analysis using specific markers for apoptosis(caspase3)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Premalignant Lesion</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with oral premalignant lesions will receive thymoquinone capsules 100mg twice daily for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with oral premalignant lesions will receive thymoquinone capsules 200mg twice daily for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients with oral premalignant lesions will receive placebo twice daily for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoquinone 100mg</intervention_name>
    <description>thymoquinone will be extracted from Nigella Sativa and packed in capsules of 100mg</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>Nigella Sativa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thymoquinone 200mg</intervention_name>
    <description>thymoquinone will be extracted from Nigella Sativa and packed in capsules of 200mg</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Nigella Sativa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>capsules with the same color and form as the active ones but without active ingredient will be given to the patients</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion Criteria:

          -  Patients with age range 18-75 years.

          -  Patients with any known potentially malignant lesion confirmed histologically and
             clinically.

        Exclusion Criteria:

          -  Patients with systemic illness.

          -  Patients received previous treatment for the condition.

          -  Current malignancy.

          -  Pregnant or lactating women.

          -  Hypersensitivity to the intervention.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fatheya Zahran</last_name>
    <role>Study Chair</role>
    <affiliation>Professor of Oral Medicine and Periodontology, Faculty of Oral and Dental Medicine, Cairo University.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Noha Ghallab</last_name>
    <role>Study Director</role>
    <affiliation>Professor of Oral Medicine and Periodontology, Faculty of Oral and Dental Medicine, Cairo University.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ghada Nabil</last_name>
    <phone>+201288667128</phone>
    <email>ghadanabil86@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Noha Ghallab</last_name>
    <phone>+201005263365</phone>
    <email>noha.ghallab@dentistry.cu.edu.eg</email>
  </overall_contact_backup>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2017</study_first_submitted>
  <study_first_submitted_qc>July 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2017</study_first_posted>
  <last_update_submitted>July 14, 2017</last_update_submitted>
  <last_update_submitted_qc>July 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ghada Nabil</investigator_full_name>
    <investigator_title>Assistant lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

